Folger Hill Asset Management Lp buys $29,354,250 stake in Insys Therapeutics Inc (INSY)

Insys Therapeutics Inc (INSY) : Folger Hill Asset Management Lp scooped up 179,807 additional shares in Insys Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 1,597,945 shares of Insys Therapeutics Inc which is valued at $29,354,250.Insys Therapeutics Inc makes up approximately 2.71% of Folger Hill Asset Management Lp’s portfolio.

Other Hedge Funds, Including , Millennium Management boosted its stake in INSY in the latest quarter, The investment management firm added 5,557 additional shares and now holds a total of 115,552 shares of Insys Therapeutics Inc which is valued at $2,122,690. Insys Therapeutics Inc makes up approx 0.01% of Millennium Management’s portfolio.Rhumbline Advisers boosted its stake in INSY in the latest quarter, The investment management firm added 1,885 additional shares and now holds a total of 28,140 shares of Insys Therapeutics Inc which is valued at $516,932.Blackrock Japan Ltd boosted its stake in INSY in the latest quarter, The investment management firm added 990 additional shares and now holds a total of 1,400 shares of Insys Therapeutics Inc which is valued at $25,718.Acrospire Investment Management boosted its stake in INSY in the latest quarter, The investment management firm added 11,095 additional shares and now holds a total of 17,095 shares of Insys Therapeutics Inc which is valued at $303,778. Insys Therapeutics Inc makes up approx 0.22% of Acrospire Investment Management’s portfolio.

Insys Therapeutics Inc opened for trading at $14.43 and hit $14.655 on the upside on Thursday, eventually ending the session at $14.36, with a gain of 0.63% or 0.09 points. The heightened volatility saw the trading volume jump to 3,71,622 shares. Company has a market cap of $1,028 M.

On the company’s financial health, Insys Therapeutics Inc reported $0.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $0.07. The company had revenue of $67.10 million for the quarter, compared to analysts expectations of $66.94 million. The company’s revenue was down -13.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.21 EPS.

Insys Therapeutics Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule a generic equivalent to Marinol (dronabinol) an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. The Company’s lead product candidate is Dronabinol oral solution an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Insys Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Insys Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.